Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma
© 2021 John Wiley & Sons Ltd..
OBJECTIVE: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics.
METHODS: About 202 severe asthmatics were studied after 12-120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO- subjects. Blood eosinophil (BE) counts after treatment were considered.
RESULTS: Pre-/post-treatment bronchodilator FEV1 % and ACT were lower (61% [50-71], 74.4% [62.5-83.7] and 20[18-22]), whereas BE were higher (380 cells/µl [170-590]) in RAO+ compared to RAO- subjects (77% [64-88], p = 0.0001, 81.8% [66.1-94.3], p = 0.0001, 21[18-23], p = 0.045 and 230 cells/µl [80-360], p = 0.003). A negative relationship between SABA-induced FEV1 % changes and pre-bronchodilator FEV1 % (β = -0.551%; p = 0.0001) and ACT (β = -0.059; p = 0.038) was found. Conversely, post-treatment BE levels were positively related (β = 145.565 cells/µl; p = 0.003) to FEV1 > 12% increases. A rising trend of pre-/post-bronchodilator FEV1 % in time was observed in RAO- subjects with BE < 300 cells/µl. Conversely, we highlighted significant declining tendencies of pre/post-bronchodilator FEV1 % in RAO+ patients with BE > 300 cells/µl reaching lower values after more than 36 months of step-5 treatment (59.6% [39.9-72.1] vs 74[66.5-89.2] of RAO+ individuals with BE < 300 cells/µl [p = 0.026] and 81.6% [66.1-91.8] of RAO-subjects with BE > 300 cells/µl [p = 0.009]).
CONCLUSION: Persistent SABA-induced FEV1 > 12%, especially when associated to BE > 300 cells/ml, may be a marker of accelerated lung function decline in severe asthmatics despite maximal step-5 treatment. The highest bronchodilation associated to the lowest BE levels should be the main goal of asthma treatment to prevent such decline.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
The clinical respiratory journal - 15(2021), 2 vom: 29. Feb., Seite 237-243 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sposato, Bruno [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergic asthma |
|---|
| Anmerkungen: |
Date Completed 18.08.2021 Date Revised 18.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/crj.13325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319642615 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319642615 | ||
| 003 | DE-627 | ||
| 005 | 20231225171903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/crj.13325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319642615 | ||
| 035 | |a (NLM)33400385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sposato, Bruno |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2021 | ||
| 500 | |a Date Revised 18.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics | ||
| 520 | |a METHODS: About 202 severe asthmatics were studied after 12-120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO- subjects. Blood eosinophil (BE) counts after treatment were considered | ||
| 520 | |a RESULTS: Pre-/post-treatment bronchodilator FEV1 % and ACT were lower (61% [50-71], 74.4% [62.5-83.7] and 20[18-22]), whereas BE were higher (380 cells/µl [170-590]) in RAO+ compared to RAO- subjects (77% [64-88], p = 0.0001, 81.8% [66.1-94.3], p = 0.0001, 21[18-23], p = 0.045 and 230 cells/µl [80-360], p = 0.003). A negative relationship between SABA-induced FEV1 % changes and pre-bronchodilator FEV1 % (β = -0.551%; p = 0.0001) and ACT (β = -0.059; p = 0.038) was found. Conversely, post-treatment BE levels were positively related (β = 145.565 cells/µl; p = 0.003) to FEV1 > 12% increases. A rising trend of pre-/post-bronchodilator FEV1 % in time was observed in RAO- subjects with BE < 300 cells/µl. Conversely, we highlighted significant declining tendencies of pre/post-bronchodilator FEV1 % in RAO+ patients with BE > 300 cells/µl reaching lower values after more than 36 months of step-5 treatment (59.6% [39.9-72.1] vs 74[66.5-89.2] of RAO+ individuals with BE < 300 cells/µl [p = 0.026] and 81.6% [66.1-91.8] of RAO-subjects with BE > 300 cells/µl [p = 0.009]) | ||
| 520 | |a CONCLUSION: Persistent SABA-induced FEV1 > 12%, especially when associated to BE > 300 cells/ml, may be a marker of accelerated lung function decline in severe asthmatics despite maximal step-5 treatment. The highest bronchodilation associated to the lowest BE levels should be the main goal of asthma treatment to prevent such decline | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a allergic asthma | |
| 650 | 4 | |a blood eosinophil | |
| 650 | 4 | |a bronchodilator reversibility | |
| 650 | 4 | |a lung function decline; severe asthma; salbutamol | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 700 | 1 | |a Scalese, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ricci, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rogliani, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Paggiaro, Pierluigi |e verfasserin |4 aut | |
| 700 | 0 | |a Omalizumab Italian Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Sposato, B |e investigator |4 oth | |
| 700 | 1 | |a Migliorini, M G |e investigator |4 oth | |
| 700 | 1 | |a Di Tomassi, M |e investigator |4 oth | |
| 700 | 1 | |a Olivieri, C |e investigator |4 oth | |
| 700 | 1 | |a Perrella, A |e investigator |4 oth | |
| 700 | 1 | |a Camiciottoli, G |e investigator |4 oth | |
| 700 | 1 | |a Maselli, R |e investigator |4 oth | |
| 700 | 1 | |a Pelaia, G |e investigator |4 oth | |
| 700 | 1 | |a Busceti, M T |e investigator |4 oth | |
| 700 | 1 | |a Sabato, E |e investigator |4 oth | |
| 700 | 1 | |a Cagnazzo, M G |e investigator |4 oth | |
| 700 | 1 | |a Colombo, F |e investigator |4 oth | |
| 700 | 1 | |a Palumbo, L |e investigator |4 oth | |
| 700 | 1 | |a Ravazzi, A |e investigator |4 oth | |
| 700 | 1 | |a Bucca, C |e investigator |4 oth | |
| 700 | 1 | |a Caiaffa, M F |e investigator |4 oth | |
| 700 | 1 | |a Berra, A |e investigator |4 oth | |
| 700 | 1 | |a Calabrese, C |e investigator |4 oth | |
| 700 | 1 | |a Stanziola, A A |e investigator |4 oth | |
| 700 | 1 | |a Schino, P |e investigator |4 oth | |
| 700 | 1 | |a Di Gioacchino, M |e investigator |4 oth | |
| 700 | 1 | |a Rogliani, P |e investigator |4 oth | |
| 700 | 1 | |a Cazzola, M |e investigator |4 oth | |
| 700 | 1 | |a Segreti, A |e investigator |4 oth | |
| 700 | 1 | |a Pastorello, E A |e investigator |4 oth | |
| 700 | 1 | |a Scibilia, G |e investigator |4 oth | |
| 700 | 1 | |a Vianello, A |e investigator |4 oth | |
| 700 | 1 | |a Marchi, M R |e investigator |4 oth | |
| 700 | 1 | |a Paladini, L |e investigator |4 oth | |
| 700 | 1 | |a Baglioni, S |e investigator |4 oth | |
| 700 | 1 | |a Abbritti, M |e investigator |4 oth | |
| 700 | 1 | |a Almerigogna, F |e investigator |4 oth | |
| 700 | 1 | |a Matucci, A |e investigator |4 oth | |
| 700 | 1 | |a Vultaggio, A |e investigator |4 oth | |
| 700 | 1 | |a Maggi, E |e investigator |4 oth | |
| 700 | 1 | |a Maestrelli, P |e investigator |4 oth | |
| 700 | 1 | |a Guarnieri, G |e investigator |4 oth | |
| 700 | 1 | |a Steinhilber, G |e investigator |4 oth | |
| 700 | 1 | |a Bonavia, M |e investigator |4 oth | |
| 700 | 1 | |a Rottoli, P |e investigator |4 oth | |
| 700 | 1 | |a Bargagli, E |e investigator |4 oth | |
| 700 | 1 | |a Senna, G |e investigator |4 oth | |
| 700 | 1 | |a Caminati, M |e investigator |4 oth | |
| 700 | 1 | |a Macchia, L |e investigator |4 oth | |
| 700 | 1 | |a Bellia, V |e investigator |4 oth | |
| 700 | 1 | |a Scichilone, N |e investigator |4 oth | |
| 700 | 1 | |a Paggiaro, P |e investigator |4 oth | |
| 700 | 1 | |a Novelli, F |e investigator |4 oth | |
| 700 | 1 | |a Latorre, M |e investigator |4 oth | |
| 700 | 1 | |a Vergura, L |e investigator |4 oth | |
| 700 | 1 | |a Masieri, S |e investigator |4 oth | |
| 700 | 1 | |a Scalese, M |e investigator |4 oth | |
| 700 | 1 | |a Rosati, Y |e investigator |4 oth | |
| 700 | 1 | |a Milanese, M |e investigator |4 oth | |
| 700 | 1 | |a Folletti, I |e investigator |4 oth | |
| 700 | 1 | |a Pio, R |e investigator |4 oth | |
| 700 | 1 | |a Pio, A |e investigator |4 oth | |
| 700 | 1 | |a Maccari, U |e investigator |4 oth | |
| 700 | 1 | |a Maggiorelli, C |e investigator |4 oth | |
| 700 | 1 | |a Scala, R |e investigator |4 oth | |
| 700 | 1 | |a Vignale, L |e investigator |4 oth | |
| 700 | 1 | |a Pulerà, N |e investigator |4 oth | |
| 700 | 1 | |a Carpagnano, G E |e investigator |4 oth | |
| 700 | 1 | |a Foschino Barbaro, M P |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The clinical respiratory journal |d 2007 |g 15(2021), 2 vom: 29. Feb., Seite 237-243 |w (DE-627)NLM19646837X |x 1752-699X |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:2 |g day:29 |g month:02 |g pages:237-243 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/crj.13325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 2 |b 29 |c 02 |h 237-243 | ||